Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib + Ofatumumab in Previously Treated CLL
NCT01659021Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Dec 2012
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of idelalisib in chronic lymphocytic leukemia (CLL) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Progression-Free Survival up to 60 months. Started Dec 2012; status: terminated.
02
Drugs
idelalisib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01659021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01659021.